Cargando…

Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments

Background. Currently, few rebiopsies are performed in relapses of advanced non-small cell lung cancer. They are not customary in clinical practice of lung cancer. However, it is not possible to properly target treatments in cases of relapse without knowing the nature of new lesions. Design. This pa...

Descripción completa

Detalles Bibliográficos
Autor principal:	Jekunen, Antti P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325200/ https://www.ncbi.nlm.nih.gov/pubmed/25699082 http://dx.doi.org/10.1155/2015/809835

Ejemplares similares

Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods
por: Zarogoulidis, Paul, et al.
Publicado: (2019)

Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy
por: Ishii, Hidenobu, et al.
Publicado: (2017)

Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer
por: Fukui, Tomoya, et al.
Publicado: (2019)

Gene-Guided Treatment Decision-Making in Non-Small Cell Lung Cancer – A Systematic Review
por: Saarenheimo, Jatta, et al.
Publicado: (2021)

The utility of transbronchial rebiopsy for peripheral pulmonary lesions in patients with advanced non-squamous non-small cell lung cancer
por: Tateishi, Akiko, et al.
Publicado: (2020)

The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
por: Saarenheimo, Jatta, et al.
Publicado: (2019)

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
por: Ichihara, Eiki, et al.
Publicado: (2018)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
por: Kawamura, Takahisa, et al.
Publicado: (2016)

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
por: Goag, Eun Kyong, et al.
Publicado: (2018)

Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
por: Pereira, Isabel, et al.
Publicado: (2020)

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review
por: Imakita, Takuma, et al.
Publicado: (2019)

Rebiopsy rate after transperineal or transrectal prostate biopsy
por: Marenco Jimenez, Jose L., et al.
Publicado: (2021)

The characteristics and spatial distributions of initially missed and rebiopsy-detected prostate cancers
por: You, Myung-Won, et al.
Publicado: (2016)

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
por: Tseng, Jeng-Sen, et al.
Publicado: (2018)

Clinicians’ Expectations for Gene-Driven Cancer Therapy
por: Jekunen, Antti
Publicado: (2014)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
por: Ahn, Hyein, et al.
Publicado: (2018)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival
por: Christopoulos, Petros, et al.
Publicado: (2019)

Current challenges in applying gene-driven therapies in clinical lung cancer practice
por: Saarenheimo, Jatta, et al.
Publicado: (2021)

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
por: Ko, Ryo, et al.
Publicado: (2016)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
por: Matsuda, Asako, et al.
Publicado: (2019)

Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets
por: Jekunen, Antti
Publicado: (2014)

Topotecan in the treatment of relapsed small cell lung cancer
por: Quoix, Elisabeth
Publicado: (2008)

Prostate Cancer Detection at Rebiopsy After an Initial Benign Diagnosis: Results Using Sextant Extended Prostate Biopsy
por: Leite, Katia Ramos Moreira, et al.
Publicado: (2008)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

FDG‐PET/CT‐guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma
por: Rajamäki, Aino, et al.
Publicado: (2022)

Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer
por: Sata, Masafumi, et al.
Publicado: (2021)

Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients
por: Kosmidis, Christoforos, et al.
Publicado: (2019)

Clinical impact of rebiopsy among patients with epidermal growth factor receptor‐mutant lung adenocarcinoma in a real‐world clinical setting
por: Nam, Yunha, et al.
Publicado: (2021)

Transrectal ultrasound-guided prostate rebiopsy: How many core sampling should be applied to which patient?
por: Amasyalı, Akın Soner, et al.
Publicado: (2018)

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds
por: Walker, Paul R.
Publicado: (2023)

Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT
por: Karagiannis, Vasileios, et al.
Publicado: (2022)

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2019)

Topotecan: An evolving option in the treatment of relapsed small cell lung cancer
por: Garst, Jennifer
Publicado: (2007)

Current and Emerging Pharmacotherapies for the Treatment of Relapsed Small Cell Lung Cancer
por: Nair, Binu S., et al.
Publicado: (2011)

Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient
por: Froudarakis, Marios E, et al.
Publicado: (2010)

Socioeconomic status and lifestyle patterns in the most common cancer types-community-based research
por: Sandström, Niclas, et al.
Publicado: (2023)

Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer
por: Chandrasekar, Divya, et al.
Publicado: (2016)

Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment
por: Eigeliene, Natalja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8tgkjc79imlinl3er6idmc6fe5